A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

June 7, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

March 3, 2027

Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
DRUG

Teclistamab

Teclistamab will be administered subcutaneously.

Trial Locations (53)

2050

Royal Prince Alfred Hospital, Camperdown

3121

Epworth Healthcare, Richmond

3128

Box Hill Hospital, Box Hill

5042

Flinders Medical Centre, Bedford Park

20251

Universitaetsklinikum Hamburg Eppendorf, Hamburg

24127

ASST Papa Giovanni XXIII Bergamo, Bergamo

25123

Azienda Ospedaliera Spedali Civili di Brescia, Brescia

28041

Hosp. Univ. 12 de Octubre, Madrid

28223

Hosp. Quiron Madrid Pozuelo, Pozuelo de Alarcón

30912

Augusta University- Georgia Cancer Center, Augusta

31008

Clinica Univ. de Navarra, Pamplona

33331

Cleveland Clinic Florida, Weston

33604

CHU de Bordeaux - Hospital Haut-Leveque, Pessac

37007

Hosp Clinico Univ de Salamanca, Salamanca

39008

Hosp. Univ. Marques de Valdecilla, Santander

44093

CHU Nantes, Nantes

44195

Cleveland Clinic, Cleveland

46237

St Francis Hospital & Health Centers Indiana Blood and Marrow Transplantation Franciscan Health, Indianapolis

47014

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola

56126

Ospedale Santa Chiara AO Universitaria Pisana, Pisa

59037

CHRU de Lille Hopital Claude Huriez, Lille

60126

Ospedali Riuniti Di Ancona, Ancona

64239

Sourasky Medical Center, Tel Aviv

69120

Universitaetsklinikum Heidelberg, Heidelberg

69495

CHU Lyon Sud, Pierre-Bénite

75246

Baylor University Medical Center, Dallas

80218

Colorado Blood Cancer Institute, Denver

85234

Banner MD Anderson Cancer Center, Gilbert

97080

Universitatsklinikum Wurzburg, Würzburg

3436212

Carmel Medical Center, Haifa

5266202

Sheba Medical Center, Ramat Gan

9112001

Hadassah University Hospita Ein Kerem, Jerusalem

T6G 1Z2

Cross Cancer Institute, Edmonton

M5G 1X6

Princess Margaret Cancer Centre University Health Network, Toronto

09113

Klinikum Chemnitz gGmbH, Chemnitz

00168

Policlinico Universitario Agostino Gemelli, Rome

21 500

Wojewodzki Szpital Specjalistyczny, Biała Podlaska

80 214

Uniwersyteckie Centrum Kliniczne, Gdansk

40 519

Pratia Onkologia Katowice, Katowice

25 734

Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach, Kielce

20 090

Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli, Lublin

53-439

Dolnoslaskie Centrum Onkologii, Wroclaw

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

06591

The Catholic University of Korea Seoul St Mary s Hospital, Seoul

08036

Hosp Clinic de Barcelona, Barcelona

08908

ICO L'Hospitalet - Hospital Duran i Reynals, Barcelona

W12 0HS

Hammersmith Hospital, London

M20 4BX

The Christie NHS Foundation Trust Christie Hospital, Manchester

NR4 7UY

Norfolk & Norwich University Hospital, Norwich

PL6 8DH

Derriford Hospital, Plymouth

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT06425991 - A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter